ZAS Onco, a division of ZAS Corporation Ltd., in collaboration with the Medical Oncology Society of Bangladesh (MOSB), recently organized a scientific seminar titled “Recent Advances in Bevacizumab Therapy: Expanding the Horizon.” The event served as a valuable platform for oncologists and cancer care professionals to discuss the evolving clinical applications and therapeutic advancements of Bevacizumab.
The seminar brought together renowned oncologists from across Bangladesh, who shared their insights, clinical experiences, and research findings surrounding Bevacizumab—a targeted therapy widely used in the treatment of various cancers, including colorectal, lung, and ovarian cancers. The engaging sessions highlighted new data, patient outcomes, and future directions of the therapy in both global and local contexts.
In his welcome address, a representative from ZAS Onco emphasized the company’s ongoing commitment to supporting evidence-based oncology practices and fostering collaboration between medical professionals and industry stakeholders. He further stated, “We believe that continuous scientific engagement is key to improving patient care and advancing treatment protocols.”
The seminar concluded with a vibrant Q&A and networking session, allowing participants to connect, reflect, and reinforce their dedication to cancer care excellence in Bangladesh.
ZAS Onco extends sincere appreciation to all participating oncologists, MOSB, and healthcare leaders who contributed to the success of this meaningful scientific event.
